SPRING-2 the future of antiretroviral therapy
- PMID: 24074643
- DOI: 10.1016/S1473-3099(13)70194-4
SPRING-2 the future of antiretroviral therapy
Comment on
-
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.Lancet Infect Dis. 2013 Nov;13(11):927-35. doi: 10.1016/S1473-3099(13)70257-3. Epub 2013 Sep 25. Lancet Infect Dis. 2013. PMID: 24074642 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
